3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
24
Urinary Bladder Neoplasms
22
Ureteral Neoplasms
8
Urologic Neoplasms
4
Urethral Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
3
Neoplasm Metastasis
3
Peripheral Nervous System Diseases
2
Muscle Invasive Bladder Urothelial Carcinoma
2
Metastatic Urothelial Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Advanced Bladder Cancer
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urachal adenocarcinoma
1
Triple Negative Breast Neoplasms
1
Salivary Gland Neoplasms
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Penile Squamous Cell Carcinoma (PSCC)
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms by Site
1
Muscle-invasive Bladder Cancer
1
Metastatic Urothelial Cancer and Other Malignant Solid Tumors
1
Interventions
enzalutamide
6
Abiraterone Acetate
6
olaparib
5
Docetaxel
5
darolutamide
4
Prednisone
4
Pluvicto
4
cabazitaxel
3
testosterone 17 beta-cypionate
2
radium Ra 223 dichloride
2
fludarabine
2
abiraterone
2
Prednisolone
2
Nivolumab
2
Cyclophosphamide
2
Androgen Antagonists
2
sipuleucel-T
1
rucaparib
1
poly ICLC
1
pamiparib
1
lactitol
1
fludarabine phosphate
1
fluciclovine F-18
1
enfortumab vedotin
1
ebastine
1
copanlisib
1
cabozantinib
1
bempegaldesleukin
1
avelumab
1
alovudine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Castration-resistant Prostate Cancer
×
enfortumab vedotin
×
Clear all
NCT04754191
2026-02-12
ENCORE
University of Utah
Phase 2
Active not recruiting
34 enrolled